Generic Drugs to Market - What's the Climate in 2014?
Pharmaceutical giant Johnson & Johnson and three of its subsidiaries have agreed to pay more than $2.2 billion in a global settlement of multiple criminal charges, civil claims and state probes relating to the false marketing...more
The Federal Trade Commission (FTC) has revised the rule for determining when a transfer of exclusive rights to a patent in the pharmaceutical industry (including biologics and medicine manufacturing) results in a potentially...more
When Japanese pharmaceutical giant Daiichi Sankyo purchased Ranbaxy Laboratories of India in 2008, they probably thought they were acquiring the goose that laid the golden egg. Instead, it seems they purchased a $46 billion...more
On April 26, 2013, the U. S. Department of Justice (DOJ) intervened in a whistleblower case alleging Novartis Pharmaceuticals Corporation (Novartis) knowingly and willfully violated the federal FCA by inducing physicians to...more
For years, the U.S. Department of Justice has aggressively pursued and brought charges over “off-label promotions”—the promotion of drugs for uses that have not received FDA approval—by pharmaceutical manufacturers and their...more
Following the Second Circuit’s marquee First Amendment ruling in the Caronia case, two recent developments demonstrate a shift in the battleground for First Amendment challenges to the prohibition on off-label promotion under...more
The government may be coming up with a new cost-effective measure to help balance the federal budget – enlisting private companies to do their policing. A 2011 settlement between the Justice Department and Google for $500...more